Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edap TMSSTU:EDA -1.65%69 Debt-to-Equity is -12.92 as of Jun. 2026. GuruFocus rates STU:EDA with a GF Score™ of 69/100 and a GF Value™ of €3.40 (Fairly Valued). The stock has 3 warning signs investors should review. Among 103 Medical Distribution companies, Edap TMS ranks worse than 970872.82% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Edap TMS's Debt-to-Equity or its related term are showing as below:
STU:EDA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -12.92 Med: 0.16 Max: 2.75
Current: -12.92
During the past 13 years, the highest Debt-to-Equity Ratio of Edap TMS was 2.75. The lowest was -12.92. And the median was 0.16.
STU:EDA's Debt-to-Equity is not ranked
in the Medical Distribution industry.
Industry Median: 0.46
vs STU:EDA: -12.92
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Edap TMS Debt-to-Equity Related Terms
Edap TMS Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Edap TMS's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:EDA vs ACH, YI, COSM: Debt-to-Equity Comparison
For the Medical Distribution subindustry, Edap TMS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Edap TMS's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edap TMS (STU:EDA) has a Debt-to-Equity of -12.92 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Edap TMS and its competitors. According to the industry distribution chart, Edap TMS ranks #999999 out of 103 companies in the Medical Distribution industry.
Is Edap TMS's Debt-to-Equity too high?
Edap TMS's current Debt-to-Equity is -12.92. Based on the distribution chart, Edap TMS ranks #999999 out of 103 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Edap TMS has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's Debt-to-Equity compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #999999 out of 103 companies for Debt-to-Equity. This places Edap TMS in the lower half of its industry. The industry median Debt-to-Equity is 0.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.46, based on 103 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Edap TMS and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current Debt-to-Equity is -12.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (STU:EDA) is currently considered Fairly Valued. The stock's GF Value™ is €3.40, compared to a current price of €3.62 — trading 6.5% above its estimated fair value. The current Debt-to-Equity is -12.92. Edap TMS's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Edap TMS (STU:EDA), the current Debt-to-Equity is -12.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (STU:EDA) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of €3.62 is trading 6.5% above its estimated GF Value™ of €3.40.
GuruFocus considers Edap TMS to be Fairly Valued.
Key valuation signals for STU:EDA:
Debt-to-Equity: -12.92
GF Value™: €3.40 vs. price of €3.62 (6.5% above fair value)
No single metric tells the full story. See the STU:EDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA is a French medical device company that develops, manufactures, and markets minimally invasive devices based on focused ultrasound technology. Its flagship product is the Focal One robotic high-intensity focused ultrasound (HIFU) platform, which combines imaging, real-time treatment planning, and robotic precision for focal therapy of prostate cancer. The company also markets the Ablatherm HIFU device for prostate cancer treatment and distributes the ExactVu micro-ultrasound system, along with lithotripsy equipment for urinary stone treatment through its urology division. Edap sells primarily to hospitals, urology clinics, and medical centers in Europe, the United States, and Asia. Revenue comes from device sales, procedure-based consumables, and maintenance and service contracts. The company is headquartered in Vaulx-en-Velin, France, and is listed on the Nasdaq under the ticker EDAP.
69GF Score
Get the complete analysis for STU:EDA
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EDA has been successfully added to your 
